ArcherDX: Invitae completes its $1.4B acquisition of Boulder-based ArcherDX
ArcherDX had previously applied for an IPO before the public company its acquisition was announced.
Read full article »
ArcherDX is a bioinformatics company that develops and commercializes NGS-based gene fusion detection assays for oncology applications.
Read more